Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
์ข
๋ชฉ ์ฝ๋ VSTM
ํ์ฌ ์ด๋ฆVerastem Inc
์์ฅ์ผNov 08, 2011
CEOPaterson (Daniel W)
์ง์ ์78
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃNov 08
์ฃผ์117 Kendrick Street
๋์NEEDHAM
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02494
์ ํ17812924200
์น์ฌ์ดํธhttps://www.verastem.com/
์ข
๋ชฉ ์ฝ๋ VSTM
์์ฅ์ผNov 08, 2011
CEOPaterson (Daniel W)